BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib

Reuters03-26

March 26 (Reuters) - Johnson & Johnson JNJ.N:

RYBREVANT® (AMIVANTAMAB-VMJW) PLUS LAZCLUZE™ (LAZERTINIB) OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTED OVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER
J&J - MEDIAN OVERALL SURVIVAL NOT YET REACHED WITH PROJECTED IMPROVEMENT OF MORE THAN ONE YEAR VERSUS OSIMERTINIB

Source text: ID:nPnbJLQP0a

Further company coverage: JNJ.N

(((( Reuters.Briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522335895?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-27 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522335895","market":"nz","top_or_hot":-1,"title":"BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-J&amp;J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib</title></head><body><p><span>March 26 (Reuters)</span><span> - </span>Johnson &amp; Johnson <span>JNJ.N</span>:</p><ul><li><p>RYBREVANT® (AMIVANTAMAB-VMJW) PLUS LAZCLUZE™ (LAZERTINIB) OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTED OVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER</p></li><li><p>J&amp;J - MEDIAN OVERALL SURVIVAL NOT YET REACHED WITH PROJECTED IMPROVEMENT OF MORE THAN ONE YEAR VERSUS OSIMERTINIB</p></li></ul><p>Source text: <span>ID:nPnbJLQP0a</span></p><p>Further company coverage: <span>JNJ.N</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-27 01:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-J&amp;J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib</title></head><body><p><span>March 26 (Reuters)</span><span> - </span>Johnson &amp; Johnson <span>JNJ.N</span>:</p><ul><li><p>RYBREVANT® (AMIVANTAMAB-VMJW) PLUS LAZCLUZE™ (LAZERTINIB) OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTED OVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER</p></li><li><p>J&amp;J - MEDIAN OVERALL SURVIVAL NOT YET REACHED WITH PROJECTED IMPROVEMENT OF MORE THAN ONE YEAR VERSUS OSIMERTINIB</p></li></ul><p>Source text: <span>ID:nPnbJLQP0a</span></p><p>Further company coverage: <span>JNJ.N</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2505996509.AUD","symbol_name":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q91BT:1","article_id":"2522335895","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522335895","pubTimestamp":1743010622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus OsimertinibMarch 26 (Reuters) - Johnson & Johnson JNJ.N:RYBREVANT (AMIVANTAMAB-VMJW) PLUS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4592":"伊斯兰概念","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","JNJ":"强生","BK4585":"ETF&股票定投概念","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","BK4007":"制药","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4581":"高盛持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H"},"translate_title":"简介-强生表示中位总生存期尚未达到，预计与奥希替尼相比改善超过一年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"BRIEF-J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus OsimertinibMarch 26 (Reuters) - Johnson & Johnson JNJ.N:RYBREVANT® (AMIVANTAMAB-VMJW) PLUS LAZCLUZE™ (LAZERTINIB) OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTED OVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCERJ&J - MEDIAN OVERALL SURVIVAL NOT YET REACHED WITH PROJECTED IMPROVEMENT OF MORE THAN ONE YEAR VERSUS OSIMERTINIBSource text: ID:nPnbJLQP0aFurther company coverage: JNJ.N (((( Reuters.Briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522335895"}